Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2113260 | Cancer Letters | 2012 | 8 Pages |
Abstract
Targeted photosensitizer delivery to EGFR-expressing cells was achieved in the present study using a high purity, targeted photoimmunoconjugate (PIC). When the PDT agent, benzoporphyrin derivative monoacid ring A (BPD) was coupled to an EGFR-targeting antibody (cetuximab), we observed altered cellular localization and selective phototoxicity of EGFR-positive cells, but no phototoxicity of EGFR-negative cells. Cetuximab in the PIC formulation blocked EGF-induced activation of the EGFR and downstream signaling pathways. Our results suggest that photoimmunotargeting is a useful dual strategy for the selective destruction of cancer cells and also exerts the receptor-blocking biological function of the antibody.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Adnan O. Abu-Yousif, Anne C.E. Moor, Xiang Zheng, Mark D. Savellano, Weiping Yu, Pål K. Selbo, Tayyaba Hasan,